Content Quality: Clean, focused FDA approval News article (481 words). All claims trace to one of two cited sources, both verified. Honest scope ('narrow in scope — limited to a specific genetic subset'). No fabrication, no orphan sources, no misattribution.
Source Verification: {"https://www.globenewswire.com/news-release/2026/05/01/3286140/0/en/Arvinas-Announces-FDA-Approval-of-VEPPANU-vepdegestrant-for-the-Treatment-of-ESR1m-ER-HER2-Advanced-Breast-Cancer.html":"source-0.html — Verified verbatim: May 01, 2026 announcement; 'first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader'; ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer indication; VERITAC-2 trial; 270 patients with ESR1 mutations; PFS 5 months vs 2.1 months; HR 0.57 (95% CI 0.42-0.77; p=0.0001); 28-day continuous dosing schedule; common AEs (decreased WBC, increased liver enzymes, musculoskeletal pain, fatigue, nausea, decreased hemoglobin); Randy Teel, Ph.D., President and CEO 'targeted protein degradation can translate into meaningful clinical impact' verbatim quote; Noah Berkowitz, M.D., Ph.D., CMO 'VEPPANU addresses an unmet need for patients with this aggressive form of breast cancer' verbatim quote; July 2021 Pfizer collaboration; September 2025 third-party commercialization plan.","https://www.biopharmadive.com/news/arvinas-pfizer-fda-approve-veppanu-vepdegestrant-breast-cancer/819108/":"source-1.html — Verified: protein-degradation mechanism description (taking unwanted proteins linked to disease and trashing them via the cell's natural waste disposal system), Arvinas shares climbed about 7% on news of the approval."}
Factual Accuracy: Headline framing, indication text, trial design, clinical data, executive quotes, partnership history, and stock movement all verified verbatim or close-paraphrased from the two cited sources. No fabrication detected. No misattribution. Two sources, two URLs in body, no orphans. The 43% PFS reduction is correctly derived from the 0.57 hazard ratio (1 - 0.57 = 0.43).
Overall Assessment: APPROVE. The cleanest article in the May 4 batch — every claim sources cleanly to one of two cited URLs, both verified verbatim. Pre-submission audit appears to have caught and removed several unsourced specifics during writing (per the bot's earlier report: 'early 2000s PROTAC origins', 'two decades', aromatase-inhibitor resistance background, 200 mg dose, Guardant360 CDx, June 5 PDUFA, fulvestrant SERD descriptor — all dropped because they were not in the cited sources). This is the v3.8.0 workflow working exactly as designed.